PharmaEngine, Inc.

4162

TW0004162003

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
91.5 ^TWD	+0.99%		+2.81%	-13.27%

Apr. 24	PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors	CI
Mar. 18	PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC	CI

PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales

April 27, 2023 at 04:25 am EDT

PharmaEngine, Inc. announced the resignation of Peter Wu, Senior Director of Marketing & Sales. Effective date is May 5, 2023.

Latest news about PharmaEngine, Inc.

PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors	Apr. 24	CI
PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC	Mar. 18	CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
PharmaEngine, Inc. Announces Consolidated Revenue Results for the Month and Year Ended December 2023	Feb. 29	CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers	23-09-22	CI
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of Pep07 for Hematological Cancers	23-08-15	CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
PharmaEngine, Inc. Announces Dividend, Payable on September 1, 2023	23-07-27	CI
PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application	23-07-11	CI
PharmaEngine, Inc. Files Post-Approval Change Application for A New Indication of ONIVYDE to TFDA	23-06-21	CI
PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA	23-06-14	CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales	23-04-27	CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Australia HREC Approves and Australia TGA Acknowledges PharmaEngine, Inc.'s Phase 1 Clinical Study of PEP07	23-03-03	CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
PharmaEngine, Inc. Announces Change of Board of Directors Chairperson	22-09-01	CI
PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022	22-08-30	CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-03	CI
Pharmaengine, Inc. Announces Dividend for 2021,Payment Date of Cash Dividend Distribution Is September 2, 2022	22-07-26	CI
Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee	22-05-27	CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-06	CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-18	CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI

PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

91.5

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMAENGINE, INC.	-13.27%	403M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research